Amedeo Smart

Free Medical Literature Service

 

Amedeo

Antiretroviral Therapy
  Free Subscription

Articles published in
Clin Infect Dis
    April 2024
  1. PEREZ-ALBA E, Iquize-Condori RC, Cantu-Hernandez JA, Alvarez-Villalobos NA, et al
    PrEP for Transgender People: A Systematic review.
    Clin Infect Dis. 2024 Apr 24:ciae226. doi: 10.1093.
    >> Share

  2. COYLE RP, Morrow M, Mann SC, Mainella V, et al
    Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons with HIV Receiving Tenofovir Alafenamide and Emtricitabine-based Antiretroviral Therapy (QUANTI-TAF).
    Clin Infect Dis. 2024 Apr 18:ciae212. doi: 10.1093.
    >> Share

  3. WOHL DA, Koethe JR, Sax PE, McComsey GA, et al
    Antiretrovirals and Weight Change: Weighing the Evidence.
    Clin Infect Dis. 2024 Apr 12:ciae191. doi: 10.1093.
    >> Share

  4. HILL A
    Which form of tenofovir should be used worldwide: TDF or TAF?
    Clin Infect Dis. 2024 Apr 12:ciae190. doi: 10.1093.
    >> Share

  5. DAMAS J, Munting A, Fellay J, Haerry D, et al
    Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide (TAF) in people with HIV.
    Clin Infect Dis. 2024 Apr 12:ciae189. doi: 10.1093.
    >> Share

    March 2024
  6. JAO J, Bonner LB, Dobinda K, Powis KM, et al
    Lower Insulin Sensitivity Through 36 Months of Life With in Utero HIV and Antiretroviral Exposure in Botswana: Results From the Tshilo Dikotla Study.
    Clin Infect Dis. 2024 Mar 26:ciae088. doi: 10.1093.
    >> Share

  7. LANDOVITZ RJ, Tao L, Yang J, de Boer M, et al
    HIV-1 Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Pooled Analysis From 72 Global Studies.
    Clin Infect Dis. 2024 Mar 14:ciae143. doi: 10.1093.
    >> Share

  8. LLIBRE JM, Jou A, Puig T
    High-level dolutegravir resistance selection on dolutegravir/lamivudine.
    Clin Infect Dis. 2024 Mar 11:ciae125. doi: 10.1093.
    >> Share

    February 2024
  9. SHAH MM, Joyce B, Plumb ID, Sahakian S, et al
    Combined protection of vaccination and nirmatrelvir-ritonavir against hospitalization in adults with COVID-19.
    Clin Infect Dis. 2024 Feb 27:ciae105. doi: 10.1093.
    >> Share

  10. SLAMA L, Barrett BW, Abraham AG, Palella FJ Jr, et al
    Incident Proteinuria differs by HIV Serostatus among Men with Pre-diabetes: The Multicenter AIDS Cohort Study.
    Clin Infect Dis. 2024 Feb 9:ciae065. doi: 10.1093.
    >> Share

    January 2024
  11. WANG R, Sun L, Wang X, Zhai Y, et al
    Rapid Initiation of Antiretroviral Therapy with Coformulated Bictegravir, Emtricitabine, Tenofovir Alafenamide Versus Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate in HIV-positive Men Who Have Sex with Men in China: Week 48 Results of the Mu
    Clin Infect Dis. 2024 Jan 17:ciae012. doi: 10.1093.
    >> Share

  12. URSENBACH A, Ruch Y, Hoellinger B, Fuchs A, et al
    Two cases of viral re-suppression after M184V + R263 K selection on DTG/3TC without treatment modification.
    Clin Infect Dis. 2024 Jan 9:ciae006. doi: 10.1093.
    >> Share

  13. HOFFMAN RM, Brummel S, Ziemba L, Chinula L, et al
    Weight changes and adverse pregnancy outcomes with dolutegravir- and tenofovir alafenamide fumarate-containing antiretroviral treatment regimens during pregnancy and postpartum.
    Clin Infect Dis. 2024 Jan 5:ciae001. doi: 10.1093.
    >> Share

  14. LEVY ME, Burrows E, Chilunda V, Pawloski PA, et al
    SARS-CoV-2 Antiviral Prescribing Gaps Among Non-Hospitalized High-Risk Adults.
    Clin Infect Dis. 2024 Jan 3:ciad796. doi: 10.1093.
    >> Share

    December 2023
  15. LAFONT E, Blez D, Bildan MA, Veyer D, et al
    Nirmatrelvir and Ritonavir combination in COVID-19 patients with advanced chronic kidney disease.
    Clin Infect Dis. 2023 Dec 30:ciad785. doi: 10.1093.
    >> Share

    November 2023
  16. VINIKOOR MJ, Hamusonde K, Muula G, Asombang M, et al
    Long-term hepatitis B and liver outcomes among adults taking tenofovir-containing antiretroviral therapy for HBV/HIV coinfection in Zambia.
    Clin Infect Dis. 2023 Nov 24:ciad654. doi: 10.1093.
    >> Share

  17. GAUSI K, Mugerwa H, Siccardi M, Montanha MC, et al
    Pharmacokinetics and safety of twice-daily ritonavir-boosted atazanavir with rifampicin.
    Clin Infect Dis. 2023 Nov 20:ciad700. doi: 10.1093.
    >> Share

  18. MISRA K, Huang JS, Udeagu CN, Forgione L, et al
    Pre-exposure prophylaxis (PrEP) use history in people with antiretroviral resistance at HIV diagnosis: Findings from New York City HIV surveillance and partner services, 2015-2022.
    Clin Infect Dis. 2023 Nov 17:ciad699. doi: 10.1093.
    >> Share

  19. SMITH-JEFFCOAT SE, Biddle JE, Talbot HK, Morrisey KG, et al
    Symptoms, viral loads, and rebound among COVID-19 outpatients treated with nirmatrelvir/ritonavir compared to propensity score matched untreated individuals.
    Clin Infect Dis. 2023 Nov 14:ciad696. doi: 10.1093.
    >> Share

  20. MEYEROWITZ EA, Li Y
    Review: The Landscape of Antiviral Therapy for COVID-19 in the Era of Widespread Population Immunity and Omicron-Lineage Viruses.
    Clin Infect Dis. 2023 Nov 9:ciad685. doi: 10.1093.
    >> Share

    October 2023
  21. AMICK AK, Eskibozkurt GE, Hosek SG, Flanagan CF, et al
    Daily Oral Human Immunodeficiency Virus (HIV) Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price.
    Clin Infect Dis. 2023 Oct 12:ciad566. doi: 10.1093.
    >> Share

    September 2023
  22. SHARMA I, Hill A
    Global HIV Incidence Analysis and Implications for Affordability using CAB-LA versus Continuous and Event-Driven Oral PrEP.
    Clin Infect Dis. 2023 Sep 4:ciad537. doi: 10.1093.
    >> Share

    August 2023
  23. GENTRY CA, Nguyen PN, Thind SK, Kurdgelashvili G, et al
    Characteristics and outcomes of US Veterans with immunocompromised conditions at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents.
    Clin Infect Dis. 2023 Aug 24:ciad504. doi: 10.1093.
    >> Share

  24. BERTON M, Bettonte S, Stader F, Decosterd L, et al
    Antiretroviral drug exposure and response in obese and morbidly obese people with HIV: a study combining modelling and Swiss HIV Cohort data.
    Clin Infect Dis. 2023 Aug 21:ciad495. doi: 10.1093.
    >> Share

  25. ZUCKERMAN NS, Bucris E, Keidar-Friedman D, Amsalem M, et al
    Nirmatrelvir resistance - de novo E166V/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir/ritonavir monotherapy leading to clinical and virological treatment failure - a case report.
    Clin Infect Dis. 2023 Aug 19:ciad494. doi: 10.1093.
    >> Share

  26. NIU X, Drain PK
    Is Higher Adherence Required for Women using Oral Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Preexposure Prophylaxis?
    Clin Infect Dis. 2023 Aug 17:ciad485. doi: 10.1093.
    >> Share

  27. CHAN GCK, Lui GCY, Wong CNS, Yip SST, et al
    Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019 (COVID-19).
    Clin Infect Dis. 2023 Aug 2:ciad371. doi: 10.1093.
    >> Share

    July 2023
  28. HAN WM, Apornpong T, Su Lwin HM, Thammapiwan S, et al
    Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis with liver fibrosis as predictors of new-onset Diabetes Mellitus in People living with HIV: A Longitudinal Cohort Study.
    Clin Infect Dis. 2023 Jul 21:ciad433. doi: 10.1093.
    >> Share

  29. ZINO L, Wit F, Rokx C, den Hollander JG, et al
    Outcomes of bariatric surgery in people with HIV: a retrospective analysis from ATHENA cohort.
    Clin Infect Dis. 2023 Jul 1:ciad404. doi: 10.1093.
    >> Share

    June 2023
  30. FAUST JS, Kumar A, Shah J, Khadke S, et al
    Oral Nirmatrelvir and Ritonavir for Covid-19 in Vaccinated, Non-Hospitalized Adults, Ages 18-50 Years.
    Clin Infect Dis. 2023 Jun 30:ciad400. doi: 10.1093.
    >> Share

  31. TSCHUMI N, Lerotholi M, Motaboli L, Mokete M, et al
    Two-year outcomes of treatment-experienced adults after programmatic transitioning to dolutegravir: longitudinal data from the VICONEL HIV cohort in Lesotho.
    Clin Infect Dis. 2023 Jun 26:ciad390. doi: 10.1093.
    >> Share

  32. WEST E, Zeeb M, Grube C, Kuster H, et al
    Sustained viral suppression with dolutegravir monotherapy over 192 weeks in patients starting combination antiretroviral therapy during primary HIV infection (EARLY-SIMPLIFIED): a randomized, controlled, multi-site, non-inferiority trial.
    Clin Infect Dis. 2023 Jun 20:ciad366. doi: 10.1093.
    >> Share

    May 2023
  33. DEL AMO J
    Question of Whether Tenofovir Disoproxil Fumarate/Emtricitabine Provides Protection Against Clinical Severity of Coronavirus Disease 2019.
    Clin Infect Dis. 2023;76:1735-1737.
    >> Share

  34. LETENDRE SL, Chen H, McKhann A, Roa J, et al
    Antiretroviral Therapy Intensification for Neurocognitive Impairment in HIV.
    Clin Infect Dis. 2023 May 15:ciad265. doi: 10.1093.
    >> Share

  35. WAALEWIJN H, Szubert AJ, Wasmann RE, Wiesner L, et al
    First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.
    Clin Infect Dis. 2023 May 9:ciad267. doi: 10.1093.
    >> Share

  36. KABORE JL, Laffont B, Diop M, Tardif MR, et al
    Real-World Effectiveness of Nirmatrelvir/Ritonavir on Covid-19-Associated Hospitalization Prevention: A Population-Based Cohort Study in the Province of Quebec, Canada.
    Clin Infect Dis. 2023 May 7:ciad287. doi: 10.1093.
    >> Share

    April 2023
  37. ALVAREZ H, Mocroft A, Ryom L, Neesgaard B, et al
    Plasma HIV-1 RNA and CD4+ T-cell counts are determinants of virological non-suppression outcomes with initial integrase inhibitor-based regimens: A prospective RESPOND cohort study.
    Clin Infect Dis. 2023 Apr 13:ciad219. doi: 10.1093.
    >> Share

    March 2023
  38. WERBEL WA, Weld ED, Advani SD, Patel PK, et al
    Your outpatient has COVID-19: what are their treatment options in the current SARS-CoV-2 variant climate?
    Clin Infect Dis. 2023 Mar 31:ciad178. doi: 10.1093.
    >> Share

  39. MIKULSKA M, Sepulcri C, Dentone C, Magne F, et al
    Triple combination therapy with two antivirals and monoclonal antibodies for persistent or relapsed SARS-CoV-2 infection in immunocompromised patients.
    Clin Infect Dis. 2023 Mar 28:ciad181. doi: 10.1093.
    >> Share

  40. WANG P, Xing H, Zhang X, Yang J, et al
    Complexity Interactions between Nirmatrelvir/Ritonavir and Voriconazole in Patients with Coronavirus Disease 2019.
    Clin Infect Dis. 2023 Mar 21:ciad159. doi: 10.1093.
    >> Share

  41. LEA AN, Leyden WA, Sofrygin O, Marafino BJ, et al
    Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 (COVID-19) Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout.
    Clin Infect Dis. 2023 Mar 2:ciad084. doi: 10.1093.
    >> Share

  42. DEL AMO J
    Question of Whether Tenofovir Disoproxil Fumarate/Emtricitabine Provides Protection Against Clinical Severity of Coronavirus Disease 2019 (COVID-19).
    Clin Infect Dis. 2023 Mar 2:ciad086. doi: 10.1093.
    >> Share

    February 2023
  43. PANDIT JA, Radin JM, Chiang D, Spencer EG, et al
    The COVID-19 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated with Nirmatrelvir Plus Ritonavir Versus Untreated Controls.
    Clin Infect Dis. 2023 Feb 22:ciad102. doi: 10.1093.
    >> Share

    January 2023
  44. AVERY EF, Kleynhans JN, Ledergerber B, Schoepf IC, et al
    Leukocyte Count and Coronary Artery Disease Events in People with HIV: A Longitudinal Study.
    Clin Infect Dis. 2023 Jan 23:ciad033. doi: 10.1093.
    >> Share

  45. ANDERSON PL, Marzinke MA, Glidden DV
    Updating the adherence-response for oral F-TDF for PrEP among cisgender women.
    Clin Infect Dis. 2023 Jan 16:ciad021. doi: 10.1093.
    >> Share

  46. ZHAO Y, Griesel R, Omar Z, Simmons B, et al
    Initial supplementary dose of dolutegravir in second-line antiretroviral therapy: a non-comparative, double-blind, randomised placebo-controlled trial.
    Clin Infect Dis. 2023 Jan 16:ciad023. doi: 10.1093.
    >> Share

  47. BONAZZETTI C, Tazza B, Gibertoni D, Pasquini Z, et al
    Relationship between immune response to SARS-CoV2 vaccines and development of breakthrough infection in solid organ transplant recipients: the CONTRAST cohort.
    Clin Infect Dis. 2023 Jan 13:ciad016. doi: 10.1093.
    >> Share

    December 2022
  48. DE SALAZAR A, Vinuela L, Fuentes A, Teyssou E, et al
    Transmitted drug resistance to integrase based first-line HIV antiretroviral regimens in the Mediterranean Europe.
    Clin Infect Dis. 2022 Dec 26:ciac972. doi: 10.1093.
    >> Share

  49. VUORIO A, Kovanen PT, Raal F
    Statin Needs to be Continued During Paxlovid Therapy in COVID-19.
    Clin Infect Dis. 2022;75:2281-2282.
    >> Share

  50. UCHIKOBA S, Yamada G, Tsuzuki S
    Methodological Concerns Regarding a Retrospective Study With Real-World Data on Paxlovid in Israel.
    Clin Infect Dis. 2022;75:2278-2279.
    >> Share

  51. CHEN HY, Chang R, Wei JC
    Epidemiological Study of the Effectiveness of Paxlovid.
    Clin Infect Dis. 2022;75:2278.
    >> Share

  52. CHOUFANY M, Weiss L, Makinson A, Roul H, et al
    Decrease in CD4 count and risk of severe morbidity in PWH with controlled viral load after initiating cART between 2006 and 2018.
    Clin Infect Dis. 2022 Dec 17:ciac939. doi: 10.1093.
    >> Share

  53. BOSCH B, Akpomiemie G, Chandiwana N, Sokhela S, et al
    Weight and metabolic changes after switching from tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC+DTG and TDF/FTC/efavirenz (EFV) to TDF/lamivudine (3TC)/DTG.
    Clin Infect Dis. 2022 Dec 15:ciac949. doi: 10.1093.
    >> Share

    November 2022
  54. THOMAS DL, Kiser JJ, Baum MM
    Long-Acting Treatments for Hepatitis B.
    Clin Infect Dis. 2022;75.
    >> Share

  55. BERENGUER J, Jarrin I, Bellon JM, Diez C, et al
    Obesity-related SNPs and weight gain following first-line antiretroviral therapy.
    Clin Infect Dis. 2022 Nov 8. pii: 6809103. doi: 10.1093.
    >> Share

  56. FORD ES, Simmons W, Karmarkar EN, Yoke LH, et al
    Successful treatment of prolonged, severe COVID-19 lower respiratory tract disease in a B-cell ALL patient with an extended course of remdesivir and nirmatrelvir/ritonavir.
    Clin Infect Dis. 2022 Nov 3. pii: 6795102. doi: 10.1093.
    >> Share

    October 2022
  57. WALSH BS, Kesselheim AS, Rome BN
    Medicaid Spending on Antiretrovirals from 2007-2019.
    Clin Infect Dis. 2022 Oct 21. pii: 6765227. doi: 10.1093.
    >> Share

  58. WATERS L, Assoumou L, Gonzalez-Cordon A, Rusconi S, et al
    Limited weight impact after switching from boosted protease inhibitors to dolutegravir in persons with HIV with high cardiovascular risk: a post hoc analysis of the 96-week NEAT-022 randomized trial.
    Clin Infect Dis. 2022 Oct 19. pii: 6763268. doi: 10.1093.
    >> Share

  59. JOHNSON KA, Okochi H, Arreguin M, Watabe J, et al
    Brief Report: Urine Tenofovir Levels Strongly Correlate with Virologic Suppression in Patients with HIV on Tenofovir Alafenamide-Based Antiretroviral Therapy.
    Clin Infect Dis. 2022 Oct 18. pii: 6762398. doi: 10.1093.
    >> Share

  60. HOFMANN E, Surial B, Boillat-Blanco N, Gunthard HF, et al
    HBV REPLICATION DURING TENOFOVIR THERAPY IS FREQUENT IN HIV/HBV-COINFECTION.
    Clin Infect Dis. 2022 Oct 15. pii: 6761485. doi: 10.1093.
    >> Share

  61. EPLING BP, Rocco JM, Boswell KL, Laidlaw E, et al
    Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.
    Clin Infect Dis. 2022 Oct 6. pii: 6749408. doi: 10.1093.
    >> Share

    September 2022
  62. HERMANS LE, Umunnakwe CN, Lalla-Edward ST, Hebel SK, et al
    Point-Of-Care Tenofovir urine Testing for the Prediction of Treatment Failure and Drug Resistance During Initial Treatment for HIV-1 Infection.
    Clin Infect Dis. 2022 Sep 22. pii: 6711553. doi: 10.1093.
    >> Share

  63. ELVSTAM O, Malmborn K, Elen S, Marrone G, et al
    Virologic failure following low-level viremia and viral blips during antiretroviral therapy: results from a European multicenter cohort.
    Clin Infect Dis. 2022 Sep 14. pii: 6696999. doi: 10.1093.
    >> Share

    August 2022
  64. PETTIT AC, Phillips PP, Kurbatova E, Vernon A, et al
    Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with HIV (S31/A5349).
    Clin Infect Dis. 2022 Aug 30. pii: 6679254. doi: 10.1093.
    >> Share

  65. YIP TCF, Lui GCY, Lai MSM, Wong VWS, et al
    Impact of the use of oral antiviral agents on the risk of hospitalization in community COVID-19 patients.
    Clin Infect Dis. 2022 Aug 29. pii: 6678124. doi: 10.1093.
    >> Share

  66. NELSON BS, Tierney C, Persaud D, Jao J, et al
    Infants Receiving Very Early ART Have High CD4 Counts in the First Year of Life.
    Clin Infect Dis. 2022 Aug 29. pii: 6678126. doi: 10.1093.
    >> Share

  67. DIRAJLAL-FARGO S, Zhao C, Labbato D, Sattar A, et al
    Longitudinal changes in subclinical vascular disease in Ugandan youth with HIV.
    Clin Infect Dis. 2022 Aug 25. pii: 6675220. doi: 10.1093.
    >> Share

  68. MASIA M, Fernandez-Gonzalez M, Agullo V, Mascarell P, et al
    HIV-1 RNA levels in rectal and seminal compartments after switching to long-acting cabotegravir plus rilpivirine: a longitudinal study.
    Clin Infect Dis. 2022 Aug 20. pii: 6672706. doi: 10.1093.
    >> Share

  69. GANATRA S, Dani SS, Ahmad J, Kumar A, et al
    Oral Nirmatrelvir and Ritonavir in Non-hospitalized Vaccinated Patients with Covid-19.
    Clin Infect Dis. 2022 Aug 20. pii: 6672670. doi: 10.1093.
    >> Share

  70. DHARAN NJ, Jin F, Vaccher S, Bavinton B, et al
    Characteristics of HIV seroconversions in a large prospective implementation cohort study of oral HIV pre-exposure prophylaxis in men who have sex with men (EPIC-NSW).
    Clin Infect Dis. 2022 Aug 19. pii: 6671581. doi: 10.1093.
    >> Share

  71. SIBERRY GK, Mofenson LM, Calmy A, Reddy UM, et al
    Use of Ritonavir-boosted Nirmatrelvir in Pregnancy.
    Clin Infect Dis. 2022 Aug 17. pii: 6668958. doi: 10.1093.
    >> Share

    July 2022
  72. MONTEJANO R, de la Calle-Prieto F, Velasco M, Guijarro C, et al
    Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe COVID-19: The PANCOVID Randomized Clinical Trial.
    Clin Infect Dis. 2022 Jul 30. pii: 6652179. doi: 10.1093.
    >> Share

  73. MARTINEZ-SANZ J, Serrano-Villar S, Muriel A, Fraile LJG, et al
    Metabolic-related outcomes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in adults with HIV: a multicenter prospective cohort study.
    Clin Infect Dis. 2022 Jul 29. pii: 6651472. doi: 10.1093.
    >> Share

  74. LI H, Gao M, You H, Zhang P, et al
    Association of nirmatrelvir/ritonavir treatment on upper respiratory SARS-CoV-2 RT-PCR negative conversion rates among high-risk patients with COVID-19.
    Clin Infect Dis. 2022 Jul 23. pii: 6649232. doi: 10.1093.
    >> Share

  75. PESKO B, Deng A, Chan JD, Neme S, et al
    Safety, and Tolerability of Paxlovid (nirmatrelvir/ritonavir) in High Risk Patients.
    Clin Infect Dis. 2022 Jul 23. pii: 6649072. doi: 10.1093.
    >> Share

  76. SEKAGGYA-WILTSHIRE C, Nabisere R, Musaazi J, Otaalo B, et al
    Decreased dolutegravir and efavirenz concentrations with preserved virological suppression in patients with TB and HIV receiving high-dose rifampicin.
    Clin Infect Dis. 2022 Jul 21. pii: 6647783. doi: 10.1093.
    >> Share

  77. HSU HY, Chen HL, Chiang CL, Lai MW, et al
    Characterization of Hepatitis B Virus in Tenofovir-Treated and Untreated Chronically Infected Mothers and Their Immunoprophylaxis Failure Infants.
    Clin Infect Dis. 2022 Jul 5. pii: 6629403. doi: 10.1093.
    >> Share

  78. SHAH N, Esber A, Sean Cavanaugh J, Agaba P, et al
    Transitioning women to first-line preferred TLD regimen is lagging in Sub-Saharan Africa.
    Clin Infect Dis. 2022 Jul 5. pii: 6631203. doi: 10.1093.
    >> Share

    June 2022
  79. BOUCAU J, Uddin R, Marino C, Regan J, et al
    Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for COVID-19.
    Clin Infect Dis. 2022 Jun 23. pii: 6614635. doi: 10.1093.
    >> Share

  80. CARLIN AF, Clark AE, Chaillon A, Garretson AF, et al
    Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment.
    Clin Infect Dis. 2022 Jun 20. pii: 6611663. doi: 10.1093.
    >> Share

  81. RANGANATH N, O'Horo JC, Challener DW, Tulledge-Scheitel SM, et al
    Rebound Phenomenon after Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease-2019 in High-Risk Persons.
    Clin Infect Dis. 2022 Jun 14. pii: 6607746. doi: 10.1093.
    >> Share

  82. CHAN P, Yoon B, Colby D, Kroon E, et al
    Immunological, Cognitive and Psychiatric Outcomes after Initiating EFV- and DTG-based Antiretroviral Therapy during Acute HIV Infection.
    Clin Infect Dis. 2022 Jun 10. pii: 6605344. doi: 10.1093.
    >> Share

  83. NAJJAR-DEBBINY R, Gronich N, Weber G, Khoury J, et al
    Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients.
    Clin Infect Dis. 2022 Jun 2. pii: 6599020. doi: 10.1093.
    >> Share

    May 2022
  84. SCEVOLA S, Imaz A, Cottrell ML, Niubo J, et al
    Doravirine Concentrations and HIV-1 RNA in the Genital Fluids of Virologically Suppressed Adults Switching to Doravirine plus Emtricitabine/Tenofovir Alafenamide.
    Clin Infect Dis. 2022 May 25. pii: 6591842. doi: 10.1093.
    >> Share

  85. BROWNE SH, Vaida F, Umlauf A, Tucker AJ, et al
    Supporting the Art: Medication Adherence Patterns in Persons Prescribed Ingestible Sensor-enabled Oral Pre-Exposure Prophylaxis to Prevent Human Immunodeficiency Virus (HIV) Infection.
    Clin Infect Dis. 2022 May 23:ciac280. doi: 10.1093.
    >> Share

  86. CHOW N, Wong D, Lai CL, Mak LY, et al
    Effect of antiviral treatment on hepatitis B virus integration and hepatocyte clonal expansion.
    Clin Infect Dis. 2022 May 20. pii: 6589784. doi: 10.1093.
    >> Share

  87. O'HALLORAN JA, Sahrmann J, Parra-Rodriguez L, Vo DT, et al
    Integrase Strand Transfer Inhibitors are Associated with Incident Diabetes Mellitus in People with HIV.
    Clin Infect Dis. 2022 May 6. pii: 6581614. doi: 10.1093.
    >> Share

    April 2022
  88. GARCIA-CREMADES M, Vucicevic K, Hendrix CW, Jayachandran P, et al
    Characterizing HIV-preventive, plasma tenofovir concentrations. A pooled participant-level data analysis from HIV pre-exposure prophylaxis (PrEP) clinical trials.
    Clin Infect Dis. 2022 Apr 26. pii: 6574602. doi: 10.1093.
    >> Share

    March 2022
  89. AMIN J, Vaccher S, Templeton DJ, Bavinton B B, et al
    Low prior exposure and incidence of hepatitis C in HIV negative gay and bisexual men taking PrEP: findings from the EPIC-NSW prospective implementation study.
    Clin Infect Dis. 2022 Mar 30. pii: 6555792. doi: 10.1093.
    >> Share

  90. BATEMAN M, Wolf A, Chimukangara B, Brust JCM, et al
    Adherence measured using electronic dose monitoring is associated with emergent antiretroviral resistance and poor outcomes in patients co-infected with HIV/AIDS and multidrug-resistant tuberculosis.
    Clin Infect Dis. 2022 Mar 30. pii: 6555759. doi: 10.1093.
    >> Share

  91. SARAVOLATZ LD, Depcinski S, Sharma M
    Molnupiravir and Nirmatrelvir-Ritonavir: Oral COVID Antiviral Drugs.
    Clin Infect Dis. 2022 Mar 4. pii: 6542722. doi: 10.1093.
    >> Share

  92. LLIBRE JM, Brites C, Cheng CY, Osiyemi O, et al
    Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With HIV-1: Week 48 Results From the Phase 3, Non-inferiority SALSA Randomiz
    Clin Infect Dis. 2022 Mar 2. pii: 6541246. doi: 10.1093.
    >> Share

    February 2022
  93. LIEBENBERG LJP, Passmore JS, Osman F, Jewanraj J, et al
    Genital immune cell activation and tenofovir gel efficacy: a case-control study.
    Clin Infect Dis. 2022 Feb 10. pii: 6526223. doi: 10.1093.
    >> Share

  94. MA J, Nance RM, Delaney JAC, Whitney BM, et al
    Current Antiretroviral Treatment Among People With Hiv In The Us: Findings From The Cnics Cohort.
    Clin Infect Dis. 2022 Feb 3. pii: 6521538. doi: 10.1093.
    >> Share

    January 2022
  95. GRIESEL R, Maartens G, Chirehwa M, Sokhela S, et al
    Corrigendum to: CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.
    Clin Infect Dis. 2022 Jan 31. pii: 6517845. doi: 10.1093.
    >> Share

  96. OSIYEMI O, De Wit S, Ajana F, Bisshop F, et al
    Efficacy and Safety of Switching to Dolutegravir/Lamivudine (DTG/3TC) Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With HIV-1: Results Through Week 144 From the Phase 3,
    Clin Infect Dis. 2022 Jan 25. pii: 6515475. doi: 10.1093.
    >> Share

  97. ODAYAR J, Orrell C, Phillips TK, Hu NC, et al
    Use of tenofovir diphosphate levels to predict viremia during the postpartum period in women living with HIV: a nested case-control study.
    Clin Infect Dis. 2022 Jan 3. pii: 6494527. doi: 10.1093/cid/ciab1068.
    >> Share

    December 2021
  98. PODANY AT, Pham M, Sizemore E, Martinson N, et al
    Efavirenz pharmacokinetics and HIV-1 viral suppression among patients receiving TB treatment containing daily high-dose rifapentine.
    Clin Infect Dis. 2021 Dec 16. pii: 6464327. doi: 10.1093/cid/ciab1037.
    >> Share

  99. HUANG YC, Sun HY, Sheng WH, Hsieh SM, et al
    Evolution of hepatitis B virus (HBV) serologic markers among antiretroviral-naive, young people living with HIV who had undergone neonatal HBV vaccination and initiated antiretroviral therapy.
    Clin Infect Dis. 2021 Dec 10. pii: 6459150. doi: 10.1093/cid/ciab1020.
    >> Share

  100. BUKKEMS VE, Necsoi C, Tenorio CH, Garcia C, et al
    Tenofovir alafenamide plasma concentrations are reduced in pregnant women living with HIV: data from the PANNA Network.
    Clin Infect Dis. 2021 Dec 5. pii: 6453382. doi: 10.1093/cid/ciab1010.
    >> Share

  101. ROMO ML, Edwards JK, Semeere AS, Musick BS, et al
    Viral load status before switching to dolutegravir-containing antiretroviral therapy and associations with HIV treatment outcomes in sub-Saharan Africa.
    Clin Infect Dis. 2021 Dec 5. pii: 6453480. doi: 10.1093/cid/ciab1006.
    >> Share

  102. JOSEPH NT, Satten GA, Williams RE, Haddad LB, et al
    The Effect of Antiretroviral Therapy for the Treatment of HIV-1 in Pregnancy on Gestational Weight Gain.
    Clin Infect Dis. 2021 Dec 3. pii: 6448917. doi: 10.1093.
    >> Share

    November 2021
  103. VAN RENSBURG R, Nightingale S, Brey N, Albertyn CH, et al
    Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS).
    Clin Infect Dis. 2021 Nov 19. pii: 6432038. doi: 10.1093.
    >> Share

    September 2021
  104. GAO Y, Kong F, Song X, Shang J, et al
    Pradefovir Treatment in Patients with Chronic Hepatitis B: Week 24 Results from a Multicenter, Double-blind, Randomized, Noninferiority, Phase 2 Trial.
    Clin Infect Dis. 2021 Sep 6. pii: 6364928. doi: 10.1093.
    >> Share

  105. BOYCE CL, Sils T, Ko D, Wong-On-Wing A, et al
    Maternal HIV drug resistance is associated with vertical transmission and is prevalent in infected infants.
    Clin Infect Dis. 2021 Sep 1. pii: 6360962. doi: 10.1093.
    >> Share

    August 2021
  106. KENDALL MA, Lalloo U, Fletcher CV, Wu X, et al
    Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection.
    Clin Infect Dis. 2021;73:706-715.
    >> Share

    July 2021
  107. MATHAD JS, Savic R, Britto P, Jayachandran P, et al
    Pharmacokinetics and Safety of Three Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women.
    Clin Infect Dis. 2021 Jul 29. pii: 6330598. doi: 10.1093.
    >> Share

  108. DEZANET LNC, Kassime R, Miailhes P, Lascoux-Combe C, et al
    Effect of viral replication and liver fibrosis on all-cause mortality in HIV/HBV coinfected individuals: a retrospective analysis of a 15-year longitudinal cohort.
    Clin Infect Dis. 2021 Jul 1. pii: 6312684. doi: 10.1093.
    >> Share

    June 2021
  109. KUHN L, Paximadis M, Da Costa Dias B, Shen Y, et al
    Predictors of cell-associated HIV-1 DNA over one year in very early treated infants.
    Clin Infect Dis. 2021 Jun 29. pii: 6311146. doi: 10.1093.
    >> Share

  110. KOETHE JR, Moser C, Brown TT, Stein JH, et al
    Adipokines, Weight Gain and Metabolic and Inflammatory Markers after Antiretroviral Therapy Initiation: ACTG A5260s.
    Clin Infect Dis. 2021 Jun 12. pii: 6297174. doi: 10.1093.
    >> Share

    May 2021
  111. ERLANDSON KM, Carter CC, Melbourne K, Brown TT, et al
    Weight Change Following Antiretroviral Therapy Switch in People with Viral Suppression: Pooled Data from Randomized Clinical Trials.
    Clin Infect Dis. 2021 May 14. pii: 6275565. doi: 10.1093.
    >> Share

  112. TOY M, Hutton D, Harris AM, Nelson N, et al
    Cost-Effectiveness of One-Time Universal Screening for Chronic Hepatitis B Infection in Adults in the United States.
    Clin Infect Dis. 2021 May 6. pii: 6270943. doi: 10.1093.
    >> Share

    April 2021
  113. BRUST JCM, Gandhi NR, Wasserman S, Maartens G, et al
    Effectiveness and cardiac safety of bedaquiline-based therapy for drug-resistant tuberculosis: a prospective cohort study.
    Clin Infect Dis. 2021 Apr 21. pii: 6244470. doi: 10.1093.
    >> Share

  114. BLUMENTHAL J, Jain S, He F, Amico KR, et al
    Results from a PrEP Demonstration Project for At-Risk Cisgender Women in the United States.
    Clin Infect Dis. 2021 Apr 17. pii: 6232085. doi: 10.1093.
    >> Share

    March 2021

  115. Erratum to: Body Composition Changes after Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s.
    Clin Infect Dis. 2021 Mar 29. pii: 6199412. doi: 10.1093/cid/ciaa1740.
    >> Share

  116. BRAZIER E, Tymejczyk O, Zaniewski E, Egger M, et al
    Effects of national adoption of Treat-All guidelines on pre-ART CD4 testing and viral load monitoring after ART initiation: A regression discontinuity analysis.
    Clin Infect Dis. 2021 Mar 9. pii: 6164944. doi: 10.1093.
    >> Share

  117. MARCONI VC, Moser C, Gavegnano C, Deeks SG, et al
    Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults with HIV.
    Clin Infect Dis. 2021 Mar 6. pii: 6159796. doi: 10.1093.
    >> Share

    February 2021
  118. KENDALL MA, Lalloo U, Fletcher CV, Wu X, et al
    Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin vs. Lopinavir/Ritonavir + Daily Rifabutin for Treatment of HIV-TB Coinfection.
    Clin Infect Dis. 2021 Feb 9. pii: 6131728. doi: 10.1093.
    >> Share

  119. STALTER RM, Baeten JM, Donnell D, Spinelli MA, et al
    Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection.
    Clin Infect Dis. 2021;72:486-489.
    >> Share

  120. RAUGI DN, Ba S, Cisse O, Diallo K, et al
    Long-term Experience and Outcomes of Programmatic Antiretroviral Therapy for Human Immunodeficiency Virus Type 2 Infection in Senegal, West Africa.
    Clin Infect Dis. 2021;72:369-378.
    >> Share

    January 2021
  121. KIRKEGAARD-KLITBO DM, Thomsen MT, Gelpi M, Bendtsen F, et al
    Hepatic steatosis associated with exposure to elvitegravir and raltegravir.
    Clin Infect Dis. 2021 Jan 25. pii: 6119572. doi: 10.1093.
    >> Share

  122. GARCIA-OTERO L, LOpez M, GoncE A, Fortuny C, et al
    Cardiac remodeling and hypertension in HIV uninfected infants exposed in utero to antiretroviral therapy.
    Clin Infect Dis. 2021 Jan 20. pii: 6104502. doi: 10.1093.
    >> Share

  123. ZENG QL, Yu ZJ, Ji F, Li GM, et al
    Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study.
    Clin Infect Dis. 2021 Jan 4. pii: 6062485. doi: 10.1093/cid/ciaa1939.
    >> Share

  124. AVETTAND-FENOEL V, Lechenadec J, Diallo MS, Fillion M, et al
    Initiating Antiretroviral Treatment Early in Infancy Has Long-term Benefits on the Human Immunodeficiency Virus Reservoir in Late Childhood and Adolescence.
    Clin Infect Dis. 2021 Jan 4. pii: 6062433. doi: 10.1093/cid/ciaa1931.
    >> Share

    December 2020
  125. LEE JS, Humes EA, Hogan BC, Buchacz K, et al
    CD4 count at entry into HIV care and at antiretroviral therapy prescription in the US, 2005-2018.
    Clin Infect Dis. 2020 Dec 31. pii: 6056679. doi: 10.1093/cid/ciaa1904.
    >> Share

  126. GREENBERG L, Ryom L, Neesgaard B, Wandeler G, et al
    Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV.
    Clin Infect Dis. 2020 Dec 23. pii: 6044711. doi: 10.1093/cid/ciaa1878.
    >> Share

  127. DICKINSON L, Walimbwa S, Singh Y, Kaboggoza J, et al
    Infant exposure to dolutegravir through placental and breastmilk transfer: a population pharmacokinetic analysis of DolPHIN-1.
    Clin Infect Dis. 2020 Dec 21. pii: 6042568. doi: 10.1093/cid/ciaa1861.
    >> Share

  128. STRANIX-CHIBANDA L, Anderson PL, Kacanek D, Hosek S, et al
    Tenofovir diphosphate concentrations in dried blood spots from pregnant and postpartum adolescent and young women receiving daily observed pre-exposure prophylaxis in sub-Saharan Africa.
    Clin Infect Dis. 2020 Dec 20. pii: 6042339. doi: 10.1093/cid/ciaa1872.
    >> Share

  129. ORKIN C, Squires KE, Molina JM, Sax PE, et al
    Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferior
    Clin Infect Dis. 2020 Dec 18. pii: 6041522. doi: 10.1093.
    >> Share

  130. BERCOT B, Charreau I, Clotilde R, Delaugerre C, et al
    High Prevalence and High Rate of Antibiotic Resistance of Mycoplasma genitalium Infections in Men who Have Sex with Men. A Sub-Study of the ANRS Ipergay PrEP Trial.
    Clin Infect Dis. 2020 Dec 11. pii: 6030928. doi: 10.1093/cid/ciaa1832.
    >> Share

    November 2020
  131. MONTEPIEDRA G, Kim S, Weinberg A, Theron G, et al
    Using a composite maternal-infant outcome measure in tuberculosis prevention studies among pregnant women.
    Clin Infect Dis. 2020 Nov 4. pii: 5955952. doi: 10.1093/cid/ciaa1674.
    >> Share

    October 2020

  132. Erratum to: Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
    Clin Infect Dis. 2020 Oct 14. pii: 5923337. doi: 10.1093.
    >> Share

    September 2020
  133. GRIESEL R, Maartens G, Chirehwa M, Sokhela S, et al
    CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.
    Clin Infect Dis. 2020 Sep 22. pii: 5909992. doi: 10.1093/cid/ciaa1073.
    >> Share

  134. IMAZ A, Tiraboschi JM, Niubo J, Martinez-Picado J, et al
    Dynamics of the decay of HIV RNA and distribution of bictegravir in the genital tract and rectum in antiretroviral-naive HIV-1-infected adults treated with bictegravir/emtricitabine/tenofovir alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 5
    Clin Infect Dis. 2020 Sep 18. pii: 5908302. doi: 10.1093/cid/ciaa1416.
    >> Share

  135. REBEIRO PF, Jenkins CA, Bian A, Lake JE, et al
    Risk of Incident Diabetes Mellitus, Weight Gain, and their Relationships with Integrase Inhibitor-based Initial Antiretroviral Therapy Among Persons with HIV in the US and Canada.
    Clin Infect Dis. 2020 Sep 16. pii: 5906580. doi: 10.1093/cid/ciaa1403.
    >> Share

    August 2020
  136. LEONARD MA, Cindi Z, Bradford Y, Bourgi K, et al
    Efavirenz Pharmacogenetics and Weight Gain following Switch to Integrase Inhibitor-containing Regimens.
    Clin Infect Dis. 2020 Aug 23. pii: 5896036. doi: 10.1093/cid/ciaa1219.
    >> Share

  137. CROWELL TA, Danboise B, Parikh A, Esber A, et al
    Pre-Treatment and Acquired Antiretroviral Drug Resistance among Persons Living with HIV in Four African Countries.
    Clin Infect Dis. 2020 Aug 12. pii: 5891786. doi: 10.1093/cid/ciaa1161.
    >> Share

  138. LU H, Cole SR, Westreich D, Hudgens MG, et al
    Clinical effectiveness of integrase strand transfer inhibitor-based antiretroviral regimens among adults with human immunodeficiency virus: a collaboration of cohort studies in the United States and Canada.
    Clin Infect Dis. 2020 Aug 11. pii: 5891141. doi: 10.1093/cid/ciaa1037.
    >> Share

  139. MARTIN TCS, Abrams M, Anderson C, Little SJ, et al
    Rapid antiretroviral therapy among individuals with acute and early HIV.
    Clin Infect Dis. 2020 Aug 10. pii: 5890460. doi: 10.1093/cid/ciaa1174.
    >> Share

  140. GRANT RM, Pellegrini M, Defechereux PA, Anderson PL, et al
    Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the iBrEATHe Study.
    Clin Infect Dis. 2020 Aug 8. pii: 5885191. doi: 10.1093/cid/ciaa1160.
    >> Share

    July 2020
  141. ENGEL T, Raffenberg M, Schoepf IC, Kootstra NA, et al
    Telomere Length, Traditional Risk Factors, HIV-related Factors and Coronary Artery Disease Events in Swiss Persons Living with HIV.
    Clin Infect Dis. 2020 Jul 29. pii: 5877846. doi: 10.1093/cid/ciaa1034.
    >> Share

  142. BEKKER A, Decloedt EH, Slade G, Cotton MF, et al
    Single Dose Abacavir Pharmacokinetics and Safety in Neonates Exposed to HIV.
    Clin Infect Dis. 2020 Jul 22. pii: 5874909. doi: 10.1093/cid/ciaa1026.
    >> Share

  143. SPINELLI MA, Lowery B, Shuford JA, Spindler J, et al
    Use of Drug-Level Testing and Single-Genome Sequencing to Unravel a Case of HIV Seroconversion on PrEP.
    Clin Infect Dis. 2020 Jul 20. pii: 5873702. doi: 10.1093/cid/ciaa1011.
    >> Share

  144. SAX PE, Rockstroh JK, Luetkemeyer AF, Yazdanpanah Y, et al
    Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV.
    Clin Infect Dis. 2020 Jul 15. pii: 5872016. doi: 10.1093.
    >> Share

  145. MORSE GD
    Strategies for Implementation Research to Investigate the Negative Pharmacokinetic Interaction Between Efavirenz and Dolutegravir.
    Clin Infect Dis. 2020 Jul 15. pii: 5871901. doi: 10.1093.
    >> Share

  146. HAAS DW, Acosta EP
    Implications of Efavirenz Pharmacogenetics when Switching from Efavirenz- to Dolutegravir-containing Antiretroviral Regimens.
    Clin Infect Dis. 2020 Jul 15. pii: 5871900. doi: 10.1093.
    >> Share

  147. ZHANG H, Wang F, Zhu X, Chen Y, et al
    Antiviral Activity and Pharmacokinetics of the HBV Capsid Assembly Modulator GLS4 in Patients with Chronic HBV Infection.
    Clin Infect Dis. 2020 Jul 10. pii: 5869864. doi: 10.1093.
    >> Share

    June 2020
  148. STALTER RM, Baeten JM, Donnell D, Spinelli MA, et al
    Urine Tenofovir Levels Measured by a Novel Immunoassay Predict HIV Protection.
    Clin Infect Dis. 2020 Jun 22. pii: 5860911. doi: 10.1093.
    >> Share

    May 2020
  149. SHALEV N, Scherer M, LaSota ED, Antoniou P, et al
    Clinical characteristics and outcomes in people living with HIV hospitalized for COVID-19.
    Clin Infect Dis. 2020 May 30. pii: 5848754. doi: 10.1093.
    >> Share

  150. ZHANG JJY, Lee KS, Ang LW, Leo YS, et al
    Risk Factors of Severe Disease and Efficacy of Treatment in Patients Infected with COVID-19: A Systematic Review, Meta-Analysis and Meta-Regression Analysis.
    Clin Infect Dis. 2020 May 14. pii: 5837140. doi: 10.1093.
    >> Share

  151. CASTILLO-MANCILLA JR
    Adherence to Antiretroviral Therapy and Pre-exposure Prophylaxis: TARGETing the Ideal Measure.
    Clin Infect Dis. 2020;70:2152-2154.
    >> Share

  152. NASUUNA E, Tenforde MW, Muganzi A, Jarvis JN, et al
    Reduction in Baseline CD4 Count Testing Following Human Immunodeficiency Virus "Treat All" Adoption in Uganda.
    Clin Infect Dis. 2020 May 5. pii: 5830931. doi: 10.1093.
    >> Share

  153. DIJKSTRA M, van Rooijen MS, Hillebregt MM, van Sighem A, et al
    Decreased time to viral suppression after implementation of targeted testing and immediate initiation of treatment of acute HIV infection among men who have sex with men in Amsterdam.
    Clin Infect Dis. 2020 May 5. pii: 5829898. doi: 10.1093.
    >> Share

    April 2020
  154. BUKKEMS V, Necsoi C, Tenorio CH, Garcia C, et al
    Clinically significant lower elvitegravir exposure during third trimester of pregnant patients living with HIV: data from the PANNA study.
    Clin Infect Dis. 2020 Apr 24. pii: 5824808. doi: 10.1093.
    >> Share

    March 2020
  155. GEORGE JM, Kuriakose SS, Monroe A, Hou Q, et al
    Utilization of Direct Oral Anticoagulants in People with HIV: Observational Data from the DC Cohort.
    Clin Infect Dis. 2020 Mar 17. pii: 5808710. doi: 10.1093.
    >> Share

  156. GORWOOD J, Bourgeois C, Pourcher V, Pourcher G, et al
    The integrase inhibitors dolutegravir and raltegravir exert pro-adipogenic and profibrotic effects and induce insulin resistance in human/simian adipose tissue and human adipocytes.
    Clin Infect Dis. 2020 Mar 13. pii: 5804258. doi: 10.1093.
    >> Share

  157. BHATTACHARYA D, Gupta A, Tierney C, Huang S, et al
    Hepatotoxicity and Liver-Related Mortality in Women of Child-Bearing Potential Living With HIV and High CD4 Counts Initiating Efavirenz-Containing Regimens.
    Clin Infect Dis. 2020 Mar 12. pii: 5803286. doi: 10.1093.
    >> Share

  158. COLLINS LF, Sheth AN, Mehta CC, Naggie S, et al
    The Prevalence and Burden of Non-AIDS Comorbidities among Women living with or at-risk for HIV Infection in the United States.
    Clin Infect Dis. 2020 Mar 2. pii: 5770982. doi: 10.1093.
    >> Share

    February 2020
  159. PINTYE J, Kinuthia J, Abuna F, Mugwanya K, et al
    Frequency and predictors of tenofovir-diphosphate detection among young Kenyan women in a real-world pre-exposure prophylaxis implementation program.
    Clin Infect Dis. 2020 Feb 28. pii: 5766394. doi: 10.1093.
    >> Share

  160. DEBROY P, Lake JE, Moser C, Olefsky M, et al
    Antiretroviral therapy initiation is associated with decreased visceral and subcutaneous adipose tissue density in people living with HIV.
    Clin Infect Dis. 2020 Feb 28. pii: 5763206. doi: 10.1093.
    >> Share

    January 2020
  161. HIRANSUTHIKUL A, Himmad L, Kerr SJ, Janamnuaysook R, et al
    Drug-drug interactions among Thai HIV-positive transgender women undergoing feminizing hormone therapy and antiretroviral therapy: the iFACT study.
    Clin Infect Dis. 2020 Jan 16. pii: 5707314. doi: 10.1093.
    >> Share

  162. MASWABI K, Ajibola G, Bennett K, Capparelli EV, et al
    Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life.
    Clin Infect Dis. 2020 Jan 12. pii: 5700870. doi: 10.1093.
    >> Share

  163. KUHN L
    Early Infant Treatment: Still a long way to go to reach HIV remission.
    Clin Infect Dis. 2020 Jan 11. pii: 5700755. doi: 10.1093.
    >> Share

  164. VAN WYK J, Ajana F, Bisshop F, De Wit S, et al
    Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing a Tenofovir Alafenamide-Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1: Phase 3, Randomized, Non
    Clin Infect Dis. 2020 Jan 6. pii: 5697294. doi: 10.1093/cid/ciz1243.
    >> Share

    December 2019
  165. HUHN GD, Crofoot G, Ramgopal M, Gathe J, et al
    Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid Initiation Model of Care for HIV-1 Infection: Primary Analysis of the DIAMOND Study.
    Clin Infect Dis. 2019 Dec 27. pii: 5687816. doi: 10.1093/cid/ciz1213.
    >> Share

  166. BOIVIN MJ, Chernoff M, Fairlie L, Laughton B, et al
    African Multi-Site 2-Year Neuropsychological Study of School-Age Children Perinatally Infected, Exposed, and Unexposed to Human Immunodeficiency Virus.
    Clin Infect Dis. 2019 Dec 18. pii: 5649306. doi: 10.1093/cid/ciz1088.
    >> Share

    November 2019
  167. WALLIS CL, Hughes MD, Ritz J, Viana R, et al
    Diverse HIV-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line ART in Resource Limited Settings.
    Clin Infect Dis. 2019 Nov 14. pii: 5625392. doi: 10.1093/cid/ciz1116.
    >> Share

  168. CUNNINGHAM EB, Hajarizadeh B, Amin J, Litwin AH, et al
    Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy.
    Clin Infect Dis. 2019 Nov 2. pii: 5611150. doi: 10.1093/cid/ciz1089.
    >> Share

    October 2019
  169. KARIYAWASAM D, Peries M, Foissac F, Eymard-Duvernay S, et al
    Lopinavir-Ritonavir Impairs Adrenal Function in Infants.
    Clin Infect Dis. 2019 Oct 21. pii: 5601427. doi: 10.1093.
    >> Share

  170. LEDDY AM, Sheira LA, Tamraz B, Sykes C, et al
    Food insecurity is associated with lower levels of antiretroviral drug concentrations in hair among a cohort of women living with HIV in the United States.
    Clin Infect Dis. 2019 Oct 14. pii: 5586763. doi: 10.1093/cid/ciz1007.
    >> Share

  171. SAX PE, Erlandson KM, Lake JE, McComsey GA, et al
    Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.
    Clin Infect Dis. 2019 Oct 14. pii: 5586728. doi: 10.1093.
    >> Share


  172. Erratum to: Urine Tenofovir Concentrations Correlate with Plasma and Relates to TDF Adherence: A Randomized Directly-observed Pharmacokinetic Trial (TARGET Study).
    Clin Infect Dis. 2019 Oct 10. pii: 5585501. doi: 10.1093.
    >> Share

  173. VAN DE VEN NS, Pozniak AL, Levi JA, Clayden P, et al
    Analysis of Pharmacovigilance Databases for Dolutegravir Safety in Pregnancy.
    Clin Infect Dis. 2019 Oct 9. pii: 5583998. doi: 10.1093.
    >> Share

    September 2019
  174. MA Q, Ocque AJ, Morse GD, Sanders C, et al
    Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid.
    Clin Infect Dis. 2019 Sep 27. pii: 5575325. doi: 10.1093.
    >> Share

  175. CROWELL TA, Pinyakorn S, Sacdalan C, Kroon E, et al
    Viral Blips after Treatment Initiation during Acute HIV Infection.
    Clin Infect Dis. 2019 Sep 24. pii: 5573105. doi: 10.1093.
    >> Share

    July 2019
  176. WINCHESTER NE, Maldarelli F, Mejia Y, Dee N, et al
    8-Day Inpatient Directly Observed Therapy for ART Failure: A Tool For Preventing Unnecessary ART Changes and Optimizing Adherence Support.
    Clin Infect Dis. 2019 Jul 11. pii: 5531519. doi: 10.1093.
    >> Share

    June 2019
  177. GANTNER P, Hessamfar M, Souala MF, Valin N, et al
    Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis.
    Clin Infect Dis. 2019 Jun 28. pii: 5525174. doi: 10.1093.
    >> Share

    May 2019
  178. KOUANFACK C, Unal G, Schaeffer L, Kfutwah A, et al
    Comparative immuno-virological and clinical responses to antiretroviral therapy between HIV-1 group O- and HIV-1 group M-infected patients (ANRS 12168 DynaMO study).
    Clin Infect Dis. 2019 May 7. pii: 5486535. doi: 10.1093.
    >> Share

    April 2019
  179. GITHINJI LN, Gray DM, Hlengwa S, Machemedze T, et al
    Longitudinal changes in Spirometry in perinatally HIV-infected South African adolescents on antiretroviral therapy.
    Clin Infect Dis. 2019 Apr 2. pii: 5424067. doi: 10.1093.
    >> Share

    March 2019
  180. COLLINS IJ
    Prevalence and clinical outcomes of poor immune response despite virologically suppressive antiretroviral therapy among children and adolescents with HIV in Europe and Thailand: cohort study.
    Clin Infect Dis. 2019 Mar 28. pii: 5421269. doi: 10.1093.
    >> Share

  181. LANZAFAME M, Lattuada E, Vento S
    DRIVE-AHEAD Trial's results and the need of a right comparator drug.
    Clin Infect Dis. 2019 Mar 20. pii: 5396025. doi: 10.1093.
    >> Share

  182. FATTI G, Grimwood A, Nachega JB, Nelson JA, et al
    Better Virological Outcomes amongst People Living with HIV Initiating Early Antiretroviral Treatment (CD4 counts >/= 500 cells/microL) in the HPTN 071 (PopART) Trial in South Africa.
    Clin Infect Dis. 2019 Mar 16. pii: 5381973. doi: 10.1093.
    >> Share

    February 2019
  183. JOYA C, Won SH, Schofield C, Lalani T, et al
    Persistent Low-Level Viremia while on Antiretroviral Therapy is an Independent Risk Factor for Virologic Failure.
    Clin Infect Dis. 2019 Feb 16. pii: 5321813. doi: 10.1093.
    >> Share

    January 2019
  184. LOCKMAN S, De Gruttola V
    Outcomes Following Pregnancy Conception on Antiretroviral Therapy: A Call for More Data.
    Clin Infect Dis. 2019;68:280-281.
    >> Share

  185. RIJNDERS BJA, Rokx C
    Antiretroviral monotherapy for HIV. Game over or future perspectives?
    Clin Infect Dis. 2019 Jan 2. pii: 5269431. doi: 10.1093/cid/ciy1136.
    >> Share

    December 2018
  186. DUBE MP, Chan ES, Lake JE, Williams B, et al
    A Randomized, Double-Blinded, Placebo-Controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed HIV Infection.
    Clin Infect Dis. 2018 Dec 10. pii: 5237474. doi: 10.1093/cid/ciy1051.
    >> Share

    November 2018
  187. LOEVINSOHN G, Rosman L, Moss WJ
    Measles Seroprevalence and Vaccine Responses in HIV-Infected Adolescents and Adults: A Systematic Review.
    Clin Infect Dis. 2018 Nov 17. pii: 5188002. doi: 10.1093.
    >> Share

    September 2018
  188. HSUE PY, Ribaudo HJ, Deeks SG, Bell T, et al
    Safety and Impact of Low-Dose Methotrexate on Endothelial Function and Inflammation in Individuals with Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314.
    Clin Infect Dis. 2018 Sep 14. pii: 5096825. doi: 10.1093.
    >> Share

  189. ROBERTSON KR, Jiang H, Kumwenda J, Supparatpinyo K, et al
    HIV Associated Neurocognitive Impairment in Diverse Resource Limited Settings.
    Clin Infect Dis. 2018 Sep 13. pii: 5096722. doi: 10.1093.
    >> Share

  190. KUMARASAMY N, Prabhu S, Chandrasekaran E, Poongulali S, et al
    Safety, tolerability and efficacy of generic dolutegravir (DTG) containing ART regimens among South Indian HIV-infected patients.
    Clin Infect Dis. 2018 Sep 5. pii: 5091239. doi: 10.1093.
    >> Share

  191. GANDHI M, Ofokotun I, Bacchetti P, Jin C, et al
    Antiretroviral concentrations in hair strongly predict virologic response in a large HIV treatment-naive clinical trial.
    Clin Infect Dis. 2018 Sep 3. pii: 5089982. doi: 10.1093.
    >> Share

    June 2018
  192. GATELL JM, Assoumou L, Moyle G, Waters L, et al
    Immediate vs. Deferred Switching from a Boosted Protease Inhibitor (PI/r) Based Regimen to a Dolutegravir (DTG) Based Regimen in Virologically Suppressed Patients with High Cardiovascular Risk or Age >/=50 years: Final 96 Weeks Results of NEAT 022
    Clin Infect Dis. 2018 Jun 14. pii: 5038116. doi: 10.1093.
    >> Share

  193. CHAMMARTIN F, Zurcher K, Keiser O, Weigel R, et al
    Outcomes of Patients Lost to Follow-up in African Antiretroviral Therapy Programs: Individual Patient Data Meta-analysis.
    Clin Infect Dis. 2018 Jun 8. pii: 5034717. doi: 10.1093.
    >> Share

    May 2018
  194. ZHAO Y, Wu Z, McGoogan JM, Sha Y, et al
    Nationwide cohort study of antiretroviral therapy timing: treatment dropout and virological failure in China, 2011-2015.
    Clin Infect Dis. 2018 May 16. pii: 4996605. doi: 10.1093.
    >> Share

  195. LAMBERT-NICLOT S, Grude M, Meynard JL, Marcelin AG, et al
    Ultrasensitive HIV-1 Viral Load as a Marker of Treatment Choice for Simplification Strategies.
    Clin Infect Dis. 2018 May 15. pii: 4996083. doi: 10.1093.
    >> Share

  196. LUONG NGUYEN LB, Yazdanpanah Y, Maman D, Wanjala S, et al
    Voluntary Community Human Immunodeficiency Virus Testing, Linkage, and Retention in Care Interventions in Kenya: Modeling the Clinical Impact and Cost-effectiveness.
    Clin Infect Dis. 2018 May 8. pii: 4994303. doi: 10.1093.
    >> Share

    April 2018
  197. LEE YL, Chen GJ, Chen NY, Liou BH, et al
    Less Severe but Prolonged Course of Acute Hepatitis A in HIV-positive Patients than HIV-negative Patients During an Outbreak: A Multicenter Observational Study.
    Clin Infect Dis. 2018 Apr 17. pii: 4972863. doi: 10.1093.
    >> Share

  198. ROY M, Holmes C, Sikazwe I, Savory T, et al
    Application of a multi-state model to Evaluate Visit Burden and Patient Stability to Improve Sustainability of HIV Treatment in Zambia.
    Clin Infect Dis. 2018 Apr 7. pii: 4964003. doi: 10.1093.
    >> Share

    March 2018
  199. BENSON CA, Andersen JW, Macatangay BJC, Mailliard RB, et al
    Safety and Immunogenicity of Zoster Vaccine Live in HIV-Infected Adults with CD4+ Cell Counts Above 200 Cells/mL Virologically Suppressed on Antiretroviral Therapy.
    Clin Infect Dis. 2018 Mar 26. pii: 4953774. doi: 10.1093.
    >> Share

  200. OUSLEY J, Niyibizi AA, Wanjala S, Vandenbulcke A, et al
    High Proportions of Patients With Advanced HIV Are Antiretroviral Therapy Experienced: Hospitalization Outcomes From 2 Sub-Saharan African Sites.
    Clin Infect Dis. 2018;66.
    >> Share

  201. CARMONA S, Bor J, Nattey C, Maughan-Brown B, et al
    Persistent High Burden of Advanced HIV Disease Among Patients Seeking Care in South Africa's National HIV Program: Data From a Nationwide Laboratory Cohort.
    Clin Infect Dis. 2018;66.
    >> Share

  202. FRIGATI L, Archary M, Rabie H, Penazzato M, et al
    Priorities for Decreasing Morbidity and Mortality in Children With Advanced HIV Disease.
    Clin Infect Dis. 2018;66.
    >> Share

  203. SIIKA A, McCabe L, Bwakura-Dangarembizi M, Kityo C, et al
    Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial.
    Clin Infect Dis. 2018;66.
    >> Share

  204. POST FA, Szubert AJ, Prendergast AJ, Johnston V, et al
    Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial.
    Clin Infect Dis. 2018;66.
    >> Share

  205. OSLER M, Hilderbrand K, Goemaere E, Ford N, et al
    The Continuing Burden of Advanced HIV Disease Over 10 Years of Increasing Antiretroviral Therapy Coverage in South Africa.
    Clin Infect Dis. 2018;66.
    >> Share

  206. CALMY A, Ford N, Meintjes G
    The Persistent Challenge of Advanced HIV Disease and AIDS in the Era of Antiretroviral Therapy.
    Clin Infect Dis. 2018;66.
    >> Share

  207. MUTOH Y, Nishijima T, Inaba Y, Tanaka N, et al
    Incomplete Recovery of CD4 count, CD4 Percentage, and CD4/CD8 ratio in HIV-Infected Patients on Long-Term Antiretroviral Therapy with Suppressed Viremia.
    Clin Infect Dis. 2018 Mar 2. pii: 4917726. doi: 10.1093.
    >> Share

  208. LETENDRE S, Bharti A, Perez-Valero I, Hanson B, et al
    Higher Anti-CMV IgG Concentrations are Associated with Worse Neurocognitive Performance During Suppressive Antiretroviral Therapy.
    Clin Infect Dis. 2018 Mar 1. pii: 4915913. doi: 10.1093.
    >> Share

    February 2018
  209. MWENDA R, Fong Y, Magombo T, Saka E, et al
    Significant Patient Impact Observed Upon Implementation of Point-Of-Care Early Infant Diagnosis Technologies in an Observational Study in Malawi.
    Clin Infect Dis. 2018 Feb 27. pii: 4911493. doi: 10.1093.
    >> Share

  210. MANUZAK JA, Gott TM, Kirkwood JS, Coronado E, et al
    Heavy Cannabis Use Associated With Reduction in Activated and Inflammatory Immune Cell Frequencies in Antiretroviral Therapy-Treated Human Immunodeficiency Virus-Infected Individuals.
    Clin Infect Dis. 2018 Feb 17. pii: 4869752. doi: 10.1093/cid/cix1116.
    >> Share

  211. GRANT RM, Mannheimer S, Hughes JP, Hirsch-Moverman Y, et al
    Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study.
    Clin Infect Dis. 2018 Feb 6. pii: 4840078. doi: 10.1093/cid/cix1086.
    >> Share

    January 2018

  212. Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs.
    Clin Infect Dis. 2018 Jan 25. pii: 4823847. doi: 10.1093.
    >> Share

  213. HOSSEINIPOUR MC, Kang M, Krown SE, Bukuru A, et al
    As-Needed versus Immediate Etoposide Chemotherapy in Combination with Antiretroviral Therapy for Mild or Moderate AIDS-associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial.
    Clin Infect Dis. 2018 Jan 22. pii: 4819203. doi: 10.1093.
    >> Share

    December 2017
  214. UNAL G, Alessandri-Gradt E, Leoz M, Pavie J, et al
    HIV-1 group O infection in France: clinical features and immunovirological response to antiretrovirals.
    Clin Infect Dis. 2017 Dec 21. pii: 4768322. doi: 10.1093/cid/cix1087.
    >> Share

  215. HUA S, Vigano S, Tse S, Zhengyu O, et al
    Pegylated IFN-alpha-induced NK cell activation is associated with HIV-1 DNA decline in ART-treated HIV-1/HCV co-infected patients.
    Clin Infect Dis. 2017 Dec 20. pii: 4767848. doi: 10.1093/cid/cix1111.
    >> Share

  216. STOCKDALE AJ, Saunders MJ, Boyd MA, Bonnett LJ, et al
    Effectiveness of protease inhibitor/nucleos(t)ide reverse transcriptase inhibitor-based second-line antiretroviral therapy for the treatment of HIV-1 infection in sub-Saharan Africa: systematic review and meta-analysis.
    Clin Infect Dis. 2017 Dec 20. pii: 4767830. doi: 10.1093/cid/cix1108.
    >> Share

  217. MA Y, Dou Z, Guo W, Mao Y, et al
    The Human Immunodeficiency Virus Care Continuum in China: 1985-2015.
    Clin Infect Dis. 2017 Dec 5. pii: 4693542. doi: 10.1093.
    >> Share

    November 2017
  218. JUMARE J, Ndembi N, El-Kamary SS, Magder L, et al
    Cognitive function among antiretroviral treatment-naive individuals infected with HIV-1 Subtype G versus CRF02_AG in Nigeria.
    Clin Infect Dis. 2017 Nov 22. pii: 4647334. doi: 10.1093/cid/cix1019.
    >> Share

  219. SMITH RX, Guha A, Vaida F, Paul RH, et al
    Prefrontal recruitment mitigates risk taking behavior in HIV infected young adults.
    Clin Infect Dis. 2017 Nov 21. pii: 4644866. doi: 10.1093/cid/cix1031.
    >> Share

    October 2017
  220. ZHAO Y, Wu Z, McGoogan JM, Shi CX, et al
    Immediate antiretroviral therapy decreases mortality among patients with high CD4 counts in China: a nationwide, retrospective cohort study.
    Clin Infect Dis. 2017 Oct 21. doi: 10.1093.
    >> Share

  221. WAKE RM, Britz E, Sriruttan C, Rukasha I, et al
    High Cryptococcal Antigen Titers in Blood are Predictive of Subclinical Cryptococcal Meningitis Among HIV-Infected Patients.
    Clin Infect Dis. 2017 Oct 5. doi: 10.1093.
    >> Share

    September 2017
  222. COLLINS IJ
    Time to switch to second-line antiretroviral therapy in children with HIV in Europe and Thailand.
    Clin Infect Dis. 2017 Sep 26. doi: 10.1093.
    >> Share

  223. SALAZAR-AUSTIN N, Hoffmann J, Cohn S, Mashabela F, et al
    Poor Obstetric and Infant Outcomes in HIV-Infected Pregnant Women with Tuberculosis in South Africa: The Tshepiso Study.
    Clin Infect Dis. 2017 Sep 26. doi: 10.1093.
    >> Share

    August 2017
  224. BALOGUN KA, Lenis MG, Papp E, Loutfy M, et al
    Elevated levels of estradiol in HIV-positive pregnant women on protease inhibitor-based regimens.
    Clin Infect Dis. 2017 Aug 24. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016